Renewed efforts in this direction could unlock new opportunities to develop these compounds as effective and sustainable alternatives to synthetic inhibitors for Cathepsin K-related conditions, such as osteoporosis and cancer. The gene discussed is CTSK; the disease is osteoporosis.